➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Express Scripts
Mallinckrodt
Harvard Business School
McKesson

Last Updated: September 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Diflucan In Dextrose 5% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00189709 ↗ Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia Completed Astellas Pharma Taiwan, Inc. Phase 3 2004-08-01 To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
NCT00189709 ↗ Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia Completed Astellas Pharma Inc Phase 3 2004-08-01 To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
NCT00350818 ↗ Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) Completed Celgene Corporation Phase 1 2005-10-01 Primary Objective: -To determine the dose and schedule combination of 5-Azacitidine, when used as maintenance treatment after allogeneic transplantation for high-risk AML / MDS. Secondary Objective: -To assess the effect of treatment on survival after allogeneic transplantation for high-risk AML / MDS.
NCT00350818 ↗ Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT) Completed M.D. Anderson Cancer Center Phase 1 2005-10-01 Primary Objective: -To determine the dose and schedule combination of 5-Azacitidine, when used as maintenance treatment after allogeneic transplantation for high-risk AML / MDS. Secondary Objective: -To assess the effect of treatment on survival after allogeneic transplantation for high-risk AML / MDS.
NCT00479947 ↗ Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status Chr Hansen A/S Phase 1 2007-05-01 Yeast vaginitis is a very common ailment affecting premenopausal women in Nigeria. This condition is more prevalent in the age group between 21-30 years. More than 75% of premenopausal women and university students are diagnosed with yeast infections annually. In most of these women, recurrent rate of vaginal candidiasis with empiric therapy, stands between 70 and 80%. In addition, resistance to anti-fungal agents is increasing at an alarming speed, particularly with species other than Candida albicans such as C tropicalis and C glabrata. The healthy vaginal environment is composed mainly of lactobacilli and when these organisms are suppressed overgrowth of a large number of pathogens occur including yeasts. In this pilot study,we hypothesize that oral administration of two well documented strains of lactobacilli (L.rhamnosis GR-1 and L.reuteri RC-14 ) given to women with recurrent yeast vaginitis, following standard therapy with fluconazole will result in a significant reduction in recurrence rate of the disease.
NCT00479947 ↗ Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status UrexBiotech Phase 1 2007-05-01 Yeast vaginitis is a very common ailment affecting premenopausal women in Nigeria. This condition is more prevalent in the age group between 21-30 years. More than 75% of premenopausal women and university students are diagnosed with yeast infections annually. In most of these women, recurrent rate of vaginal candidiasis with empiric therapy, stands between 70 and 80%. In addition, resistance to anti-fungal agents is increasing at an alarming speed, particularly with species other than Candida albicans such as C tropicalis and C glabrata. The healthy vaginal environment is composed mainly of lactobacilli and when these organisms are suppressed overgrowth of a large number of pathogens occur including yeasts. In this pilot study,we hypothesize that oral administration of two well documented strains of lactobacilli (L.rhamnosis GR-1 and L.reuteri RC-14 ) given to women with recurrent yeast vaginitis, following standard therapy with fluconazole will result in a significant reduction in recurrence rate of the disease.
NCT00479947 ↗ Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status Faith Mediplex Phase 1 2007-05-01 Yeast vaginitis is a very common ailment affecting premenopausal women in Nigeria. This condition is more prevalent in the age group between 21-30 years. More than 75% of premenopausal women and university students are diagnosed with yeast infections annually. In most of these women, recurrent rate of vaginal candidiasis with empiric therapy, stands between 70 and 80%. In addition, resistance to anti-fungal agents is increasing at an alarming speed, particularly with species other than Candida albicans such as C tropicalis and C glabrata. The healthy vaginal environment is composed mainly of lactobacilli and when these organisms are suppressed overgrowth of a large number of pathogens occur including yeasts. In this pilot study,we hypothesize that oral administration of two well documented strains of lactobacilli (L.rhamnosis GR-1 and L.reuteri RC-14 ) given to women with recurrent yeast vaginitis, following standard therapy with fluconazole will result in a significant reduction in recurrence rate of the disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Diflucan In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Diflucan In Dextrose 5% In Plastic Container
Intervention Trials
Candidiasis 4
Healthy 3
Bioequivalence 2
Candidemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Diflucan In Dextrose 5% In Plastic Container
Intervention Trials
Candidiasis 7
Mycoses 3
Leukemia 2
Vaginitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Diflucan In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Diflucan In Dextrose 5% In Plastic Container
Location Trials
United States 23
Canada 3
Switzerland 2
Korea, Republic of 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Diflucan In Dextrose 5% In Plastic Container
Location Trials
New York 3
Minnesota 2
Texas 2
North Carolina 2
Louisiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Diflucan In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Diflucan In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2 2
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Diflucan In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 6
Unknown status 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Diflucan In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Diflucan In Dextrose 5% In Plastic Container
Sponsor Trials
Pfizer 3
Dr. Reddy's Laboratories Limited 2
Bayer 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Diflucan In Dextrose 5% In Plastic Container
Sponsor Trials
Other 17
Industry 14
NIH 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Mallinckrodt
McKinsey
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.